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Evidence Based Medicine

My patient has a lot of variability in his blood pressure measurements? Should
I be worried? What can I do which may be better?
Quratulain Shaikh, Ayeesha Kamran Kamal
Stroke Service and Vascular Fellowship Program, International Cerebrovascular Translational Clinical Research Training Program
(Fogarty International Center and National Institute of Neurologic Disorders and Stroke), Aga Khan University Hospital, Karachi, Pakistan.

Why is this important?
Hypertension is a strong risk factor for stroke. In
literature most work on hypertension has been done
targeting either the Systolic blood pressure, Mean blood
pressure or Pulse pressure but the ideal value which best
measures the effect of anti-hypertensive drugs and predicts
outcome in terms of complications and mortality has not
been identified yet. Two international trials, ASCOT-BPLA
and MRC, have been analyzed by investigators who have
defined that blood pressure variability when measured is
able to predict the outcome and have shown that "beta
blockers" are showing a negative effect on stroke risk by
affecting blood pressure variability and that Calcium
channel blockers may in fact be better as they have shown
to decrease the stroke risk in this sub analysis by decreasing
intrapatient variability.
ASCOT-BPLA compares amlodipine based
regimens with atenolol based regimens in patients with
hypertension and other vascular risk factors. MRC trial
compares the effect of atenolol based and diuretic based
regimens with versus placebo in hypertensive patients

Who were the participants?
ASCOT-BPLA 19257 patients were included in the
study over a period of approximately 5 years and the study was
halted early because of all cause mortality reduction benefit the
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risk of stroke. Ages were between 40 and 79 years (mean 63
yrs) with 77% males. MRC 4396 hypertensive patients
between the ages of 65-74 years were included in the study.

What were the outcomes?
ASCOT-BPLA Greater blood pressure reductions
seen with amlodipine than atenolol attributable to decrease
in blood pressure variability and leading to a reduction in all
cause mortality and stroke risk. Amlodipine was able to
reduce the mean Systolic blood pressure more than atenolol
(p< 0.0001) with lesser visit to visit variation (p< 0.0001)
and greater decrease in stroke risk than atenolol.
MRC Systolic blood pressure and all measures of
within individual variation of blood pressure were higher in
atenolol group compared with both the placebo group and
the placebo group and diuretic group (p<0.0001). There was
no effect on stroke risk in the first 2-3 years of the study
although the early risk of stroke was reduced substantially
in groups assigned to diuretics.

What were the conclusions?
The study shows that effects of specific
antihypertensive drug classes on within individual
variability of blood pressure can explain the differences in
clinical efficacy consistent with findings in other reviews of
published data. Stabilization of blood pressure is more
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important and the new target for drug development.

What does this mean for clinicians practicing
in Pakistan?
Hypertension is presently one in four Pakistani
persons over the age of 45. Control of Hypertension reduces
all-cause mortality, stroke, and MI and end stage renal
disease. Besides noting an absolute reduction in blood
pressure, we as clinicians should be looking for variability
in individual blood pressure and giving medications to
reduce the same. Spreading out regimens, looking at
sustained and longer acting agents and asking patients to
provide more intense reading records may be a way forward
supported by the current evidence.
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